

July 25, 2023

**Settlement Agreement over lawsuits on PD-L1 and CTLA-4 antibody patents  
with AstraZeneca**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “ONO”) announced that ONO and Bristol Myers Squibb (New Jersey, USA: “BMS”) signed an agreement with AstraZeneca UK Limited and MedImmune Ltd. (Cambridge, UK) and certain of their affiliates to completely and globally settle the infringement lawsuits and disputes over the PD-L1 and CTLA-4 antibody patents owned by ONO and BMS.

Ono will receive approximately 140 Million US dollars in total as a result of this settlement.

The impact on the consolidated financial results of Fiscal Year 2023 ending March 2024 will be disclosed at the announcement of financial results of the second quarter for Fiscal Year 2023 ending September 2023.

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

[public\\_relations@ono-pharma.com](mailto:public_relations@ono-pharma.com)